Last updated: March 12, 2026
What Is the Drug Identified by NDC 65162-0555?
NDC 65162-0555 corresponds to Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg. This combination treatment targets HIV-1 infections and is marketed under the brand name Descovy.
Market Landscape
Current Market Size and Sales Data
- Global HIV treatment market: Estimated at $22.3 billion in 2022 [1].
- U.S. HIV medication market: Accounted for approximately $9.2 billion in 2022, with Descovy representing roughly 10% of that revenue [2].
- Product Sales (2022):
- Descovy: Estimated US sales around $920 million.
- Market penetration: Descovy holds an approximate 25% share among fixed-dose antiretrovirals (FDCs) for HIV in the U.S. [3].
Competitive Landscape
- Key competitors:
- Gilead Sciences' Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- GlaxoSmithKline's Tivicay (Dolutegravir)
- ViiV Healthcare's Tivicay and Triumeq
- Market Differentiators:
- Efficacy profiles
- Side effect profiles
- Dosing convenience
- Patent status and exclusivity periods
Patent and Regulatory Status
- Patent protection: Immediate patent filings are typically valid for 20 years. Patent expiration for Descovy is projected around 2028-2030 [4].
- FDA approvals:
- Original approval date: October 2016.
- Recent supplemental approvals: Expanded indications for PrEP in certain populations.
Pricing Data
- Average wholesale price (AWP): Approximately $2,300 per month for a 30-day supply.
- Actual transaction price: Negotiated discounts can reduce this to below $2,000 per month.
- Patient out-of-pocket costs: Vary by insurance, often between $50 and $150 per month post-copay assistance.
Price Projection Analysis
Factors Influencing Future Pricing
-
Patent expirations and generics:
- Patent cliffs expected around 2028-2030.
- Entry of generics anticipated to reduce prices by 60-80% [5].
-
Market competition:
- Increased use of generic formulations will drive prices downward.
- Launch of biosimilars or alternative formulations by competitors can influence market share.
-
Regulatory and policy changes:
- Government initiatives to lower drug prices may impose price caps or negotiating leverage on Medicare/Medicaid.
- Patent litigations or patent challenges could accelerate generic entry.
-
Manufacturing and R&D costs:
- Costs remaining stable; significant reductions unlikely without loss of exclusivity.
Price Trajectory Scenarios
| Scenario |
Timing |
Price Point (Monthly) |
Key Drivers |
| Optimistic |
2024-2026 |
$2,000 |
Sustained brand demand, minimal discounting |
| Moderate |
2027 |
$1,700 |
Beginning patent expiry, generic competition emerges |
| Pessimistic |
2028+ |
$800 |
Widespread generic entry, market saturation, price competition |
Future Revenue Estimates
- 2023-2025: US sales continue around $900–$1 billion annually.
- Post-2028: Market share declines with generic entry; revenue drops by approximately 50–70%, assuming price drops and volume increases.
Summary of Market and Pricing Outlook
- Descovy's current dominance in the HIV FDC market reflects high efficacy and brand loyalty.
- Patent expiration around 2028-2030 likely triggers significant price reductions.
- Market penetration and competition dynamics will primarily influence future pricing and revenues.
- Price decline forecasts by 2030 suggest potential reductions of over 50%, aligning with typical patterns observed post-generic approvals.
Key Takeaways
- The drug corresponding to NDC 65162-0555 is a leading HIV treatment option with substantial current market share.
- Price projections indicate stability until patent expiry, after which aggressive price reductions are expected.
- Market competition, patent status, and regulatory shifts will significantly shape future pricing and revenue streams.
FAQs
1. When will generic versions of Emtricitabine and Tenofovir Alafenamide become available?
Generics are likely around 2028-2030, depending on patent litigation and regulatory approvals.
2. How will patent expiration affect the drug’s price?
Patent expiration typically leads to a 60-80% price drop due to generic competition and market saturation.
3. What are the main competitors for Descovy in the HIV treatment space?
Biktarvy, Tivicay, and Triumeq.
4. What factors could prevent price declines post-patent expiration?
Limited generic competition, market consolidation, or regulatory delays could slow price declines.
5. How does the drug price compare internationally?
International prices are generally lower, reflecting regional regulations, patent laws, and market dynamics.
References
[1] GlobalData. (2022). HIV Treatment Market Report.
[2] IQVIA. (2022). U.S. Prescription Drug Market Data.
[3] Gilead Sciences Investor Relations. (2022). Quarterly Revenue Reports.
[4] FDA. (2023). Patent Status of Descovy.
[5] EvaluatePharma. (2022). Generic Drug Price Trends.
